Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 13 August 2009, Vol. 114, No. 7, pp. 1374-1382.
Prepublished online as a Blood First Edition Paper on June 11, 2009; DOI 10.1182/blood-2009-05-220814.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2009-05-220814v1
114/7/1374    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Costinean, S.
Right arrow Articles by Croce, C. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costinean, S.
Right arrow Articles by Croce, C. M.
Related Collections
Right arrow Lymphoid Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

LYMPHOID NEOPLASIA

Src homology 2 domain–containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eµ-MiR-155 transgenic mice

Stefan Costinean1,*, Sukhinder K. Sandhu1,*, Irene M. Pedersen2, Esmerina Tili1, Rossana Trotta1, Danilo Perrotti1, David Ciarlariello1, Paolo Neviani1, Jason Harb1, Lauren Rachel Kauffman1, Aaditya Shidham1, and Carlo Maria Croce1,3

1 Comprehensive Cancer Center, The Ohio State University, Columbus; 2 Division of Biological Sciences, University of California-San Diego, La Jolla; and 3 Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus

We showed that Eµ-MiR-155 transgenic mice develop acute lymphoblastic leukemia/high-grade lymphoma. Most of these leukemias start at approximately 9 months irrespective of the mouse strain. They are preceded by a polyclonal pre–B-cell proliferation, have variable clinical presentation, are transplantable, and develop oligo/monoclonal expansion. In this study, we show that in these transgenic mice the B-cell precursors have the highest MiR-155 transgene expression and are at the origin of the leukemias. We determine that Src homology 2 domain–containing inositol-5-phosphatase (SHIP) and CCAAT enhancer-binding protein β (C/EBPβ), 2 important regulators of the interleukin-6 signaling pathway, are direct targets of MiR-155 and become gradually more down-regulated in the leukemic than in the preleukemic mice. We hypothesize that miR-155, by down-modulating Ship and C/EBPβ, initiates a chain of events that leads to the accumulation of large pre-B cells and acute lymphoblastic leukemia/high-grade lymphoma.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
M. T. Bolisetty, G. Dy, W. Tam, and K. L. Beemon
Reticuloendotheliosis Virus Strain T Induces miR-155, Which Targets JARID2 and Promotes Cell Survival
J. Virol., December 1, 2009; 83(23): 12009 - 12017.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020